Back

Prevalence of SELECT-eligibility and incidence of 5-year major adverse cardiovascular outcomes in non-diabetic patients with myocardial infarction

27 August 2023 (12:15 - 12:50)
Organised by: Logo
Congress Presentation Part of: Risk factors: obesity (1) Obesity ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Michael Maeng

Aarhus University Hospital, Aarhus (Denmark)

5 More presentations in this session

Presentation thumbnail
Epicardial fat is associated with adverse ventricular remodeling and diastolic dysfunction in women with ischemia but no obstructive coronary artery disease
Miss S. Zamani (Arlington, US)
Abstract Slides Video
Presentation thumbnail
Association between body mass index and outcomes in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
Doctor G. Ferrannini (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Five-year changes in weight and risk of atrial fibrillation in women and men from the Danish diet, cancer, and health cohort
Ms T. Frederiksen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
DOACs or warfarin use in morbidly obese patients (BMI > 40 kg/m2) on anticoagulant therapy? : a systematic review and meta-analysis
Doctor M. Sagris (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Effect of diabetes duration on subclinical target organ damage in young diabetic adults with type 1 diabetes mellitus
Doctor E. Kowalczyk (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors: obesity (1)

The Event

Event poster

ESC Congress 2023

27 August 2023 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular outcomes in a SELECT-like obesity population: real-world insights from the swedish AROS study
thumbnail
Congress Presentation
Eligibility for semaglutide according to the SELECT trial in a Portuguese cohort of acute coronary syndrome
thumbnail
Congress Presentation
GLP-1 RA as first-line therapy to improve outcomes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources